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STUDIES ON THE MOLECULAR MECHANICS OF INSULIN RESISTANCE IN PANCREATOGENIC
DIABETES. Ajay V. Maker, Michael Eisenberg, Kumudesh C. Sritharan, John P. Geibel, Bhanu P. Jena, and
Dana K. Andersen. Departments of Surgery and Physiology, Yale University School of Medicine, New Haven,
CT.
Chronic Pancreatitis (CP) and surgical alteration of the pancreas results in altered glucose metabolism
(pancreatogenic diabetes). ~ 70% of patients with CP develop oral glucose intolerance and -20% require
insulin therapy. Previous experiments have shown altered expression and availability of hepatic insulin receptor
(IR) and glucose transporter 2 (GLUT2) in CP, however, the cellular mechanism of resistance has not been
established. To assess whether changes in IR and GLUT2 phosphorylation mediate glucoregulatory
dysfunction, rats with CP (n=12), induced by 99% oleic acid injection into the pancreatic ducts, and shamoperated rats (n=12) were studied. Animals were fasted 24 hours, with half of each group fed intraduodenally
prior to liver harvest. IR and GLUT2 were isolated from the liver homogenates by immunoprecipitation with
anti-IR or anti-GLUT2 antibodies and probed for phosphorylated tyrosine (P-Tyr) or phosphoserine (P-Ser)
residues respectively. Total tissue phosphotyrosine phosphatase (PTPase) activity was measured by the
paranitrophenyl phosphate assay. To determine if IR and GLUT2 organized spatially in a receptor/transporter
complex, the proteins were analyzed with immunofluorescence confocal microscopy and coimmunoprecipitation. IR-P-Tyr increased 24-fold after feeding in sham animals, but increased only 13-fold in
CP.

Similarly, GLUT2-P-Ser increased ~5-fold in sham tissues, but demonstrated minimal phosphorylation in

CP animals. This corresponded to -12-fold less IR-P-Tyr (p<0.05) and almost 5-fold less IR-P-Ser (p<0.05) in
pancreatitic animals vs. sham animals in response to feeding. Total PTPase activities were not different.
Confocal microscopy demonstrated colocalization of IR and GLUT2 on the hepatocyte membrane and the
proteins coimmunoprecipitate significantly over a ubiquitous hepatocyte control protein (p<0.05). These data
confirm that hepatic IR and GLUT2 are normally phosphorylated in vivo on tyr and ser residues, respectively,
upon feeding. This phosphorylation is impaired in livers from rats with CP, and the absence of altered PTPase
activity suggests that impaired IR-Tyr kinase activity may contribute to the inappropriate hepatic glucose
production seen in pancreatogenic diabetes secondary to CP. This parallel defect in phosphorylation implies a
spatial and chemical relationship, and coimmunofluorescence and coimmunoprecipitation confirm their
colocalization on the hepatocyte membrane, providing evidence for a receptor/transporter complex.
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Introduction

In 1788, Thomas Cawley observed glycosuria in a “free living young man” who
died of emaciation and diabetes (1,2). The post mortem exam revealed multiple
pancreatic calculi and atrophy of the pancreas. These initial observations were
confirmed by other physicians, and the critical role of the pancreas in diabetes was
definitively confirmed in 1889 when Minkowski and Von Mering demonstrated that
pancreatic extirpation in dogs led to acute diabetes (3). In 1909 the name “insulin” was
proposed for a hypothetical substance secreted by the islets named by Langerhans, and
the hormone was isolated and characterized in 1922 by Banting and Best, who
administered their crude preparation to pancreatectomized dogs (4). It has been two
centuries since Cawley’s early description of diabetes secondary to chronic pancreatitis,
and thousands of reports on the disease have been published in the literature, however,
glucose intolerance in “...chronic pancreatitis remains an enigmatic process of uncertain
pathogenesis, unpredictable clinical course, and unclear treatment.” (5)
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Chronic Pancreatitis

Classification and Pathology
Chronic pancreatitis (CP) is a progressive and irreversible inflammatory disease
resulting in permanent damage to the exocrine and endocrine function of the pancreas
(6). It is distinguished from acute pancreatitis by structural and functional parameters. In
acute pancreatitis, the gland reverts to normal despite an attack, whereas, in CP, the
gland is abnormal before or after the attack, or both (7).
Morphologically, CP is characterized by acute inflammation, edema, and necrosis
superimposed upon chronic fibrosis, inflammation, and loss of exocrine tissue (see figure
1). The ductal system may be dilated and obstructed with calcified protein plugs (see
figures 2 and 3) (5, 7). Severe atrophy of the acini and fibrous replacement of the islets
is often seen in the advanced CP patient. Beta cell mass is usually reduced, and it has
been shown that a 20% reduction of beta cell mass is seen in CP. In severe forms of CP,
a marked loss of endocrine as well as exocrine tissue can occur, and usually results in a
deficiency of all islet cell hormones, in addition to insulin (8-13).
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Figure 1: Photomicrographs of the Human Pancreas
The top panel shows normal pancreatic tissue, and the lower panel shows changes in chronic pancreatitis,
characterized by a marked increase in interlobular fibrous tissue, atrophy of the acini, and a chronic
inflammatory infiltrate (H&E x95) (5).

Prevalence and Causes
CP is clinically silent in a number of individuals and many other patients with
abdominal pain elude diagnosis. Still, mean estimates of prevalence worldwide are up to
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5% of the population in one study (14). Variation in the level of alcohol consumption
worldwide and non-uniform diagnostic criteria have made the true epidemiology of the
disease unclear, however, one large scale study based on autopsies in Denmark estimate
a mean prevalence of 13% with a range from ,2%-66% in that country (15).
The causes of CP are many. In some developed countries, 60-70% of patients
present with a 6-12 year history of heavy (150-175 grams per day) alcohol consumption
(5), inspiring Freidrich to coin the term “drunkard’s pancreas” in 1878. Furthermore, the
rise in the prevalence of CP in Denmark correlates with a parallel rise in the amount of
alcohol consumption in the country (16). CP also occurs secondary to obstruction of the
pancreatic duct. The many etiologies include recurrent gallstone pancreatitis, pancreas
divisum, post-traumatic strictures, pseudocysts, morphological changes in the sphincter,
and tumors. Furthermore, CP may occur in patients with cystic fibrosis or CFTR gene
mutations, tropical ingestion of cassava fruit cyanogens, hyperparathyroidism, and
various hereditary diseases of autosomal dominance with incomplete penetrance (14).
Some of these gene mutations involve the cationic trypsinogen gene, which inhibits
enzymatic inactivation, and permits intrapancreatic autodigestion (6).

A significant

minority of all CP cases, however, remain idiopathic in nature (5).

Pathogenesis
Secretions of the diseased gland contain a disproportionally high level of protein
from acinar cells compared to concentrations of fluid and bicarbonate secretion from
ductal cells (17). As a result, this protein precipitates within the ductal network. The

5

Figure 2: Abdominal CT scan in a patient with CP
CT scan of the abdomen shows gross enlargement of the pancreatic duct (arrow). This patient has CP
with a stricture due to a carcinomatous mass in the head of the pancreas (6)

Figure 3: ERCP in a patient with CP
An endoscopic retrograde pancreatogram in a patient with CP, revealing a dilated, tortuous main duct that
contains stones or protein plugs (lucencies marked by short arrows). A stricture is visible (long arrow) as
is a dilatation of the uncinate process branch (thick arrow) (5).

precipitate eventually progresses into a laminar plug composed of necrotic cells (see
figure 3). Calcium carbonate may precipitate in the amorphous plug, forming the
characteristic intraductal stones (see figure 4).
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Figure 4: Abdominal X-Ray in a patient with CP
Plain radiograph of the abdomen showing diffuse calcifications throughout the pancreas (arrows) in an
alcoholic patient with CP (5).

Pancreatogenic Diabetes

The pancreas is critical for the control of glucose metabolism, and
pancreatectomy always produces diabetes mellitus (8). The loss of functional pancreatic
tissue in CP correlates linearly with the presence of diabetes, so that the greater the
destruction of endocrine tissue, the greater the glucose intolerance (18). Thus, 70% of
CP patients with calcifications demonstrate overt diabetes, another 20% have abnormal
glucose tolerance tests, and another 8% have impaired insulin secretion (9, 16, 19, 20).
In the absence of calcifications, the total number affected drops from 98% to -75% (20).
This glucose intolerance secondary to pancreatic resection or destruction is referred to as
pancreatogenic diabetes.

7

Pancreatogenic diabetes occurs due to a decrease in beta cell reserve, causing a
reduction in the maximum capacity for insulin release, and is not secondary to an
impaired threshold for insulin secretion, as is seen in Type II (non-insulin dependent
diabetes mellitus, NIDDM) (20). Although there is a loss of beta cell responsiveness to
glucose, the pancreatogenic diabetes seen in CP differs from the glucose intolerance seen
in type I (insulin dependent diabetes mellitus, IDDM) and type II NIDDM in that it is
brittle, rarely induces ketoacidosis, is prone to severe insulin-induced hypoglycemia due
to impaired glucagon secretion, and is characterized by a deficiency of all islet cell
hormones (18, 21-23). Pancreatogenic diabetes also demonstrates little or no insulin
response to feeding, as opposed to adult onset diabetes patients, whose response to a
carbohydrate load is exaggerated and whose plasma insulin levels are normal or elevated
(see table 1) (8). Additionally, the classic diabetic complications of retinopathy,
nephropathy, and microangiopathy are less common in these patients (18, 24, 25).

Type I
IDDM
Juvenile onset

Ketoacidosis
Hyperglycemia
Hypoglycemia
Peripheral Insulin
Sensitivity
Hepatic Insulin
Sensitivity
Insulin Levels
Glucagon Levels
PP Levels
Typical Age of Onset

Type II
NIDDM

Type III
Pancreatogenic

Adult onset

Postoperative
onset

Common

Rare

Rare

Severe

Usually Mild

Mild

Common

Rare

Common

Normal or Increased

Decreased

Increased

Normal

Normal or Decreased

Decreased

Low

High

Low

Normal or High

Normal or High

Low

High

High

Low

Childhood or Adolescence

Adulthood

Any

Table 1: Comparison of types of diabetes mellitus
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Hepatic Insulin Resistance in Pancreatogenic Diabetes
The liver is essential for regulation of metabolic homeostasis. Its central role in
control of glucose production and transport in response to stress, fasting, and feeding is
fundamental for proper glucose metabolism. This role of the liver is dependent on
pancreatic glucoregulatory hormones. Surgical alteration or destruction of the pancreas
alters the balance of the hormones, insulin, glucagon, and pancreatic polypeptide, in the
body, resulting in a disruption of net hepatic glucose production and utilization by
tissues (8).
High rates of hepatic glucose production have been shown to contribute to the
abnormal glucose tolerance seen in pancreatogenic diabetes. In fact, there remains a
high rate of hepatic glucose production in patients with CP despite physiologic levels of
insulin (26, 27). Clinical and laboratory models of pancreatic resection and CP have
consistently demonstrated a loss of hepatic sensitivity to insulin, resulting in
unsuppressed hepatic glucose production (28). As seen in figure 5, normal animals have
an exquisitely sensitive response to insulin, decreasing hepatic glucose production by up
to 95%, while subjects with pancreatogenic diabetes demonstrate only a 30%
suppression in response to the hormone (29). In addition, basal glucose production is
seen to be elevated in patients with pancreatogenic diabetes despite normal peripheral
glucose uptake, suggesting that the insulin resistance is specific for the liver (30, 31).
Ex-vivo isolated, single pass liver perfusion studies have examined the hepatic sensitivity
to insulin in the absence of extrahepatic confounders, demonstrating a loss of insulin
induced inhibition of hepatic glucose production in pancreatogenic diabetic animals (28,
32). In these euglycemic glucose-clamp studies, sham operated rats responded to an
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insulin infusion with a dose dependent suppression of hepatic glucose production, while
CP rats demonstrated uninhibited hepatic glucose production (28). Together, these
results confirm that pancreatogenic diabetes is associated with a primary hepatic
resistance to insulin.

Figure 5: Hepatic Glucose Production
Both groups of animals begin at the same basal rates of hepatic glucose production. In response
to an insulin infusion there is an exquisitely sensitive response and almost complete suppression of hepatic
glucose production (y-axis) in normal dogs, whereas, pancreatitic animals show an impairment in the
insulin mediated suppression of hepatic glucose production (29, 31).

Insulin Action

Insulin action initiates a large number of specific effects on a broad spectrum of
target cells. These effects can be divided into four pathways: 1) Stimulation of
membrane transport processes (ions, glucose, amino acids); 2) Anabolic effects via
glycogen synthesis, lipogenesis, and protein synthesis; 3) Anti-catabolic effects
inhibiting glycogenolysis, lipolysis, and proteolysis; and 4) Growth promoting effects via
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stimulation of nucleic acid synthesis (33). All of these various effects are initiated by the
binding of insulin to a specific insulin receptor (IR), potentiating a wave of signal
transduction at a post-binding level. The finding that insulin was internalized upon
binding to the IR opened a new field of research in glucose metabolism; that of the
implication of insulin binding and endocytosis in the physiopathology of diabetes and
insulin resistant states (34-37).

The Insulin Receptor
The insulin receptor is comprised of two extracellular alpha (Mr= 135 kDa) and
two transmembrane beta (Mr = 95 kDa) subunits, linked together by sulfide bonds to
create a heterotetrameric complex (36, 38, 39). Binding of insulin to the alpha subunit
extracellular domain of the insulin receptor induces a conformational change and
transmits a signal across the plasma membrane, activating a receptor kinase located on
the intracellular beta subunit (see figure 6) (40-42).

The receptor then autoactivates and

initiates a series of transphosphorylation reactions where beta subunits phosphorylate
adjacent tyrosine residues. It has been suggested that specific tyrosine residues have
distinct functions upon phosphorylation. For instance, carboxy tail residues have been
shown to be critical to the mitogenic effects of insulin.
The autophosphorylation of IR on tyrosine residues results in the phosphorylation
and dephosphorylation of many downstream cellular protein substrates (38, 43-47). This
tyrosine kinase activity of the IR beta subunit may mediate many or all of the effects of
insulin via a phosphorylation cascade, and/or through direct covalent and noncovalent
protein interactions (42, 48).
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Functional domains of the insulin receptor
The alpha subunit of the IR exists in two isoforms, with the binding domain
located in amino acids a.a.83-103. Insulin interaction with the receptor is further
modulated by cysteine rich regions, lysine a.a.460, and key amino acid sequences at the
C-terminal end (33).
The beta subunit of the IR contains 620 amino acids, 403 of which are a well
preserved intracytoplasmic sequence containing the tyrosine kinase domain. This
sequence contains thirteen tyrosine (tyr) residues, six of which become phosphorylated
upon insulin binding (33, 49). Tyrosines at 1158, 1162, and 1163 in figure 6 contain 5060% of the phosphate after IR ligand binding, and are crucial for autoactivation of the
tyrosine kinase (33). Of note, it is also postulated that serine phosphorylation at amino
acids 1293 and 1294 and threonine phosphorylation at 1336 may induce a
conformational change, thereby inhibiting IR kinase activity (33).

Insulin resistance
Insulin resistance occurs when normal physiologic concentrations of the beta cell
secreted hormone are insufficient to effect appropriate systemic responses (13, 50). By
definition, then, insulin resistance is dysfunctional signal transduction by the IR, due to
abnormalities in the ligand (insulin), the IR itself, or post-IR events (51).

12

Figure 6: The Insulin Receptor
Insulin binds to the extracellular alpha subunit and induces a conformational change, activating a receptor
kinase located on the intracellular beta subunit. Six of the thirteen tyrosine residues on the beta subunit,
labeled here according to their location in the amino acid chain, are autophosphorylated upon insulin
binding. Dephosphorylation of the same residues by tyrosine phosphatases may modulate the insulin
response. A. Maker
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Various models of cellular insulin resistance, including melanoma cell lines,
obese animal models, animal models of insulinopenic diabetes, and cells from patients
with severe insulin resistance type A; demonstrate defects in the insulin receptor kinase
(33). In the case of obesity, studies demonstrate diminished insulin binding to plasma
membrane receptors (52-58), a decrease in the number of IR’s, and normal ligand
affinity (59, 60), while in non-obese diabetic animals and in gestational diabetes, the
degree of insulin resistance correlates with decreased numbers of cell surface IR’s (6164). However, in patients with glucose intolerance secondary to long term glucocorticoid
administration, the observed decrease in insulin binding is secondary to diminished IR
affinity for its ligand (65). Furthermore, changes in IR expression, binding,
phosphorylation state and/or kinase function may be responsible for these and other
insulin resistant phenotypes (51).
In addition, it is possible that inhibition of specific tyrosine residues occurs. This
is most evident in mutations in the tyrosine kinase domains of the insulin receptor that
result in dominantly inherited forms of insulin resistance including the type A syndrome,
leprechaunism, Rabson-Mendenhall syndrome, and lipoatrophic diabetes (66).

Proximal insulin receptor signaling events
The activated IR functions as a tyrosine kinase on a number of proximal substrate
proteins. These include members of the insulin receptor substrate protein family
(IRS 1/2/3/4), the She adaptor protein isoforms, the SIRP family members, Gabl, Cbl,
and APS. This downstream signaling induces mitogenic effects via IRS dependent or
She (src homology and collagen) dependent pathways, i.e., via Grb2, SOS, ras, rafl,

14

MEK, and Erk (see figure 7).

Metabolic effects are also transduced by IRS signals

stimulating glucose transport and glycogen synthesis. Much work on IRS1 and IRS2 has
been performed and some of their unique metabolic functions have been identified. In
IRS-1 knockout mice, for example, mild states of insulin resistance are observed (67),
while IRS-2 knockout mice demonstrate frank diabetes with impaired insulin secretion
and peripheral insulin resistance (68). It is possible this discrepancy is due to a
prominence of IRS1 in skeletal muscle mediation of insulin action, while IRS2
demonstrates prominence in the liver (69).
Phosphorylated IRS proteins contain recognition sites for various cell signaling
proteins containing Src homology 2 domains, including Grb2, Nek, SHP2 protein
tyrosine phosphatase, and phosphatidylinositol 3 kinase (PI3 kinase). These multiple
proteins have been studied extensively to evaluate how they couple growth factor
stimulation to intracellular signaling pathways, and to characterize their location and role
in the insulin induced cascade. However, much remains to be elucidated.

Downstream signaling events
The function of type 1A PI3 kinase has been extensively investigated using
pharmacological inhibitors, blocking antibodies, and expression of dominant interfering
and constitutively active mutants (51). These studies conclude that PI3 kinase is
necessary for glucose uptake in skeletal muscle and adipocytes via stimulation of GLUT4
translocation from an intracellular pool to the cell surface (70). Moreover, impaired PI3
kinase activity in GLUT1 containing vesicles in fibroblasts from a patient with Werner’s
syndrome is associated with defective translocation/docking of GLUT1 with the cell
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membrane, possibly causing the molecular defect responsible for insulin resistance in the
disease. Nawano and his colleagues examined the critical role of the liver in glucose
homeostasis in the Zucker diabetic fatty rat. Their group concluded that chronic
hyperglycemia reduces the efficiency of PI3 kinase activation of the serine/threonine
kinase Akt / Protein Kinase B (Akt/PKB), and that this mechanism accounts for
hyperglycemia induced insulin resistance in the liver (71).
Furthermore, current research has shown a 40-55% decrease in insulin stimulated
tyrosine phosphorylation of IRS1 and PI3 kinase activity in type 2 diabetic patients,
which implicates decreased glucose transport with decreased phosphorylation of
molecules downstream to the phosphorylated IR and upstream to the glucose transport
proteins.
Although the downstream targets of PI3 kinase are controversial, the
serine/threonine kinase Akt (PKB) has been identified as one such protein substrate.
Normal expression of Akt in 3T3L1 adipocytes allows GLUT4 localization to the plasma
membrane, whereas the dominant mutant Akt disrupts glucose fluxes in the adipose
tissue by inhibiting GLUT4 translocation (51, 72). PI3 kinase activation of protein
kinase C is also thought to play a role in peripheral glucose metabolism, however, the
exact mechanisms are uncertain (see figure 7).

The role of protein tyrosine phosphatases
Protein tyrosine phosphatases (PTPase’s) reset pharmacologically important
tyrosine kinase receptors to their original dephosphorylated state. Active research is
investigating the tyrosine phosphatases specific to dephosphorylate the insulin receptor
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(73). Working in conjunction with serine/threonine kinases, these PTPase’s may be
intimately involved in modulating the IR’s proximal signal cascade.

IR

Figure 7: A Schematic of the IR Phosphorylation Cascade
Insulin binds to the IR, inducing autophosphorylation of the intracellular beta subunit. The tyrosine kinase
activity of the activated IR phosphorylates insulin receptor substrates, initiating a cascade of events
including stimulation of PI3 kinase and Akt/PKB. The effects of IR kinase action effect glucose transport,
protein regulation, translocation, glucose metabolism, gene expression, and mitogenesis.

Glucose Transport Protein 2 (GLUT2)

At least eight functional mammalian facilitated hexose carriers (GLUTs) have
been identified by molecular cloning, and their specificity and affinity have been
characterized. GLUT2, a 52 kDa protein encoded on chromosome 3, is found in tissues
carrying large glucose fluxes, such as intestine, kidney, liver, and beta-cells, and
facilitates membrane transport of the polar glucose molecule over a wide range of
glucose concentrations via an energy-independent mechanism (74-78). The rate of
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glucose uptake into the cell increases in proportion to the rise in blood glucose above the
physiologic range due to the transporter’s low affinity (Km=17) (79).
In the normal animal, it is believed that insulin binding to its receptor propagates
a cascade of signals, resulting in translocation of glucose transporters from an
intracellular pool to the cell membrane where they dock, fuse, and are activated, as
previously described in the case of GLUT 4 (80, 81). Models of streptozotocin induced
diabetes have not resulted in dysfunction of hepatic GLUT2, however, trafficking of the
transporter is affected in CP, with decreased internalization of the protein seen in the
diseased state versus normal animals (82). The failure of insulin mediated removal of
GLUT2 off the hepatocyte membrane in CP has been shown to directly correlate with the
unsuppressed hepatic glucose production seen in the disease state (32, 82), possibly
implying that GLUT2 is normally removed from the cell membrane in response to
insulin.
Molecular models studying glucose transport proteins have correlated
translocation and changes in glucose transport with changes in the phosphorylation state
of the GLUT protein, though no such mechanism has been demonstrated for hepatic
GLUT2. In vitro, beta cell GLUT2 has been shown to be activated through the cAMP
cascade, and glucose transport into the cell may be modulated by protein kinase A
dependent phosphorylation of serine and threonine residues on GLUT2, however, much
remains to be elucidated (see figure 8) (83).
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GLUTs Response to Insulin
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Figure 8: GLUTs response to insulin
Insulin binding to the insulin receptor stimulates the peripheral uptake of glucose and inhibits
hepatic glucose production, glycogenolysis. and gluconeogenesis. In the adipocyte and skeletal muscle
cell, insulin binding stimulates translocation of GLUT4 to the cell membrane via a series of
phosphorylation reactions including PI3 kinase and Akt/PKB, thereby allowing glucose influx into the cell.
On the other hand, insulin binding to the hepatocyte IR may stimulate endocytosis of GLUT2, inhibiting
glucose efflux. Past studies have correlated serine phosphorylation of GLUT2 with decreased glucose
transport in beta cells, and we implicate GLUT2 phosphorylation with decreased glucose transport in
hepatocytes. A. Maker
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Summary, Statement of Purpose, and Hypothesis

Summary
Impaired function of the tyrosine kinase domains of the insulin receptor
frequently results in insulin resistance. Clinically, acquired dysfunction of the insulin
receptor’s response to insulin stimulation results in glucose intolerance and a diabetic
state. Previous experiments in our laboratory have suggested that this impairment of
glycemic control may in fact be due to dysfunction of the stimulated insulin receptor and
membrane bound GLUT2.
Aberrant protein expression is not solely responsible for the observed insulin¬
signaling defects in glucose transport seen in CP or diabetes. In fact, various models of
insulin resistance and diabetes mellitus have demonstrated that the expression of insulin
receptor, IRS-1, IRS-2, MAP kinase, and glycogen synthase are similar between type 2
diabetic and control subjects. Although there is evidence to support that peripheral
insulin resistance is secondary to impaired recruitment of intracellular pools of GLUT 4
in skeletal muscle and adipose tissue in diabetes mellitus models, the defect may lie in
signaling of the translocation.
Multiple studies in various models of insulin resistance have demonstrated
phosphorylation defects at various points in the IR kinase cascade. In particular, it has
been shown that the PI3 kinase activation of protein kinase B/Akt is critical to the
translocation of glucose transport protein 4 (GLUT4) in response to insulin, and that
impaired phosphorylation of PKB/Akt creates an insulin resistant state. The exact
mechanisms of cell signaling have yet to be elucidated, however, similar models have
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been implied in GLUT 1 and 3. It is clear that GLUT2 is intimately responsible for
sensing glucose levels and effecting appropriate beta cell secretion of insulin, and it has
been shown that hepatic GLUT2 is critical for controlling hepatic glucose production,
however, the control of GLUT2 expression and function is unclear. Though studies in
glucose transport activity have been correlated with GLUT2 phosphorylation state, there
has been no evidence to support a direct link between IR and GLUT2.

Statement of purpose and hypothesis
We propose that the endpoint of one IR kinase phosphorylation cascade may be
the hepatic glucose transporter 2 (GLUT2). Our lab has observed impaired endocytosis
of GLUT2 in response to feeding without changes in GLUT2 expression in diabetic
models, further strengthening the argument for a defect in cell signaling upstream of the
glucose transporter (84). We hypothesized that autophosphorylation of the IR in
response to ligand binding sets up a phosphorylation cascade, similar to that implicated
for GLUT4, with GLUT2 being intimately connected, both chemically and spatially, with
the hepatic IR. We therefore suspected that the pancreatogenic diabetes characteristic of
CP is caused by defects in both IR-kinase stimulation and GLUT2 phosphorylation.

Therefore, we hypothesize that:
1.

Feeding activates IR and GLUT2 phosphorylation in vivo.

2. The impaired response to insulin and glucoregulatory dysfunction seen in CP may
have a basis in insulin receptor dysfunction at the level of tyrosine
autophosphorylation.
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3. The uninhibited hepatic glucose production seen in CP has a basis in dysfunctional
cell signaling, resulting in impaired GLUT2 serine phosphorylation.
4.

IR and GLUT2 interact as a functional unit in a receptor/transporter complex, and, as
such, are intimately associated spatially as a functional unit in a receptor/transporter
complex.

Our first objective was to establish that the hepatic insulin resistance and
unsuppressed glucose production characteristic of pancreatogenic diabetes is associated
with dysfunction in hepatic IR tyrosine autophosphorylation (IR-P-Tyr) and/or GLUT2
serine phosphorylation (GLUT2-P-Ser) in vivo. In the current study, a rodent model of
CP that mimics the physiological state of human CP was used to compare
phosphorylation states of IR-Tyr and GLUT2-Ser residues in control and CP rats in
response to feeding. We also intended to demonstrate an intimate spatial relationship
between GLUT2 and IR in the normal rat hepatocyte using double-labeled fluorescent
dye confocal imaging and co-immunoprecipitation techniques.
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Methods

Phosphorylation Studies

Animals
Chronic pancreatitis was induced in 150-200 gram male Sprague Dawley rats
(n=12) (Charles River, Raleigh, NC). A 2.5 cm midline abdominal incision was made,
the loop of the duodenum was mobilized, and the sphincter of Oddi identified. Fifty pL
of 99% oleic acid (Sigma Chemical Company, St. Louis, MO) was infused at 12.5
uL/minute for 4 minutes into the cannulated pancreatic duct at laparotomy, according to
the method of Mundlos et al (85). An atraumatic clamp was applied to the common
hepatic duct at its bifurcation to prevent reflux of oleic acid into the liver. Age and
weight matched sham-operated animals (n=12), that underwent laparotomy and
manipulation of the pancreas only, served as controls. Animals were explored for gross
confirmation of CP prior to sacrifice. Histologic verification of chronic pancreatitis has
been confirmed previously in this model (see figure 9). Intraperitoneal anesthesia was
sodium pentobarbital (0.07mg/g body weight).

Liver Harvest
Fifty-nine to sixty-six days post-induction, rats were fasted 24 hours in metabolic
cages, weighed, and anesthetized. All animals underwent a ventral midline incision, a
2mm gastrotomy incision, and transgastric duodenal intubation. Fed animals received a
bolus meal (0.5cc/100g) of nutritional supplement (Osmolite HN, Ross Products
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Division, Columbus, OH) injected intraduodenally over a 1 -2 minute period with
circumferential pyloric pressure to prevent reflux. Fasted animals underwent duodenal
intubation alone. Thirty-five minutes after intubation, a 2 gram section of the distal
aspect of the left main lobe of the liver was excised, rinsed in Ringers

Figure 9: Pathological and histological verification of chronic pancreatitis in the rat model
In the normal animal (upper panel), there is healthy pancreatic tissue in the loop of the duodenum
obscuring the common bile duct. Normal islets and acini are verified histologically. However, in the CP
animal (lower panel), there is loss of parenchyma in the loop of duodenum, demonstrated here by the clear
visibility of the common bile duct through the scant areas of remaining tissue. There is a loss of pancreatic
mass, blunting of lobules, and fibrous replacement. Histology confirms fibrosis, fat replacement of
exocrine tissue, and inflammation of the gland.

lactate solution, and promptly minced, homogenized, and strained at 4 °C in 2.5 mL of
fresh homogenization buffer (10 mM triethanolamine, 10 mM acetic acid pH 7.4, 1 mM
EDTA, 250 mM sucrose, 1 mM PMSF, 1 mM DTT, 1 mM Benzamadine, 10 mM
sodium orthovanadate, and 1 micromolar Okadaic acid). PMSF and benzamadine were

*
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included as protease inhibitors, and DTT as a reducing agent. Vanadate was added to
inhibit active ATPases and phosphate transferring enzymes (86, 87), and okadaic acid
was titered to inhibit active protein phosphatases completely and specifically once the
tissue was procured (88). Protein content was assayed according to the Bradford
reaction (89) and 1 mg of total protein homogenate was immediately solubilized in 1 mL
of 0.1% Triton X-100 (BioRad, Hercules, CA) at 4 °C.
Animals were paired in sham and CP groups to insure liver harvest at comparable
days post-CP induction and handling under similar conditions. Livers from paired
animals were harvested concomitantly and samples were run on the same electrophoresis
gels to minimize intra-assay variation.

Immunoprecipitation
Five mg of Protein A immobilized on sepharose CL-4B beads (Sigma Chemical
Company, St. Louis, MO) were suspended in a 20 pL slurry of PBS and incubated at
room temperature with 10 pL of antibody to the IR beta chain (InsulinR Beta C-19,
Santa Cruz Biotechnology, Santa Cruz, CA) or to GLUT2 (Biogenesis, Sandown, NH)
for 30 minutes. Solubilized samples were centrifuged at 14,000 rpm at 4 °C for 5
minutes, after which 0.5 mg of homogenate was added to the beads. Samples were
incubated for two hours on a rotating platform at 4 °C. Samples were then washed twice
at room temperature with 0.9 mL of buffer, containing 400 mM NaCl, 50 mM Tris/HCl,
and 0.02% sodium azide as a preservative (pH 7.5), and followed by two more washes of
0.9 mL of buffer containing 500 mM NaCl, 10 mM Tris/HCl, and 0.02% sodium azide
(pH 7.5). Samples were centrifuged for 3.5 minutes at 10,000 rpm at 4 °C between
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resuspensions. The series of four washes was followed by resuspension in SDS reducing
buffer for 30 minutes at room temperature. A four minute 12,000 rpm centrifugation
separated the sample from the bead pellet (see figure 10). Negative control proteins were
precipitated concomitantly.

Electrophoresis and Immunoblotting
Immunoprecipitated samples for IR were incubated in a 100 °C water bath for five
minutes. All samples and negative antibody controls were run on a 4-15% stacking gel
(BioRad, Hercules, CA) for 33-40 minutes at 200 volts (25-45 mA). Samples to be
probed for IR and phosphotyrosine were run on the same gel as were samples to be
probed for GLUT2 and phosphoserine.

Electrophoresed samples were transferred to a

nitrocellulose support at 100V for one hour, then blocked with 3% high purity bovine
serum albumin (Sigma) and probed with 1:1000 (200 pg/mL) anti-phosphotyrosine
antibody (Santa Cruz Biotechnology) or 1:6000 (37mg/mL stock concentration) antiphosphoserine antibody (Sigma). Concomitantly, blots were blocked with 3% milk and
probed with 1:1000 anti-IR antibody (Santa Cruz Biotechnology) or 1:50000 antiGLUT2 antibody (Biogenesis). HRP linked secondary antibody was analyzed with the
ECL immunodetection system (Amersham Life Science Ltd., Buckinghamshires,
England). Protein bands were analyzed with scanning densitometry (Personal
Densitometer, Molecular Dynamics, Sunnyvale, CA) and ImageQuaNTIM software
(Molecular Dynamics).

♦
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Figure 10: Immunoprecipitation of the insulin receptor
Fresh homogenized liver tissue is added to a slurry of beads coated with antibody to the insulin receptor.
A series of washes with graded salt concentrations specifies the antibody-IR interaction. The purified IR
can then be eluted from the beads, run on a SDS-PAGE gel, and probed with two antibodies; one to
quantify the amount of phosphorylated tyrosine, and the other to quantify the total amount of IR purified
from the homogenate. A Maker

Phosphatase activity
Total non-IR specific tissue phosphotyrosine phosphatase (PTPase) activity was
determined in liver homogenates by the para-nitro phenylphosphate (p-NPP) method, pNPP is a colorless compound that forms a yellow color reaction when dephosphorylated.
In our assay, 1 mg/mL p-NPP in 50mM imidazole buffer, pH 7.4, was used. Three
different concentrations of total homogenates were assayed by mixing with 100 pL of the
assay mixture in 1.5 mL Eppendorf tubes at 30 °C for 30 minutes. The reaction was
terminated by the addition of 100 pL of 0.2N NaOH. The optical density of the resultant
mixture is measured at 410nm, to determine relative PTPase activity in each sample.

♦

27

Colocalization Studies

Liver harvest and tissue preparation for confocal studies
300-400 gram male Sprague Dawley rats were anesthetized intraperitonealy with
sodium pentobarbital (0.07mg/g body weight). At laparotomy, the distal aspect of the
right main lobe of the liver was excised, rinsed in Ringers lactate solution, and promptly
minced at 4 °C. Samples were processed in 72% sucrose solution and re-equilibrated in
phosphate buffered saline at the time of sectioning.
Tissue was snap frozen in blocks for sectioning on a sliding cryostat and cut in 5
micron sections. Sections were fixed in cold acetone and rehydrated in 120 mM
phosphate solution for 40 minutes. Samples were then blocked with 8% bovine serum
albumin in 120 mM phosphate solution and 0.7% Triton-X for one hour.

Immuno staining
Primary antibodies to GLUT2 (goat anti-GLUT2, Santa Cruz Biotechnology,
Santa Cruz, CA) and IR (rabbit anti-IR, Santa Cruz Biotechnology, Santa Cruz, CA)
were prepared in a 1:20 dilution in 1% BSA-120mM phosphate, and incubated overnight
at 4 °C. Slides were then washed and incubated with donkey anti-goat IgG fluorescein
(FITC) conjugated antibody (1:100, Santa Cruz) and donkey anti-rabbit Texas Red
conjugated antibody (1:100, Santa Cruz) in the dark for three hours at room temperature.
Slides were then washed, mounted with glycerol-PBS, and placed at 4 °C until imaged.
Specimens were viewed on a Zeiss LSM Axiovert 100 confocal microscope (Zeiss,
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Germany) with a 60x water immersion lens. Images were displayed at 512x512 pixels
and processed using Adobe Photoshop v. 5.5 software. FITC was stimulated at 488 nm
and emission collected with a 515-565 nm filter system in accordance with peak
excitation and emission spectra for the fluorochrome. Similarly, Texas Red was
stimulated at 568nm and emission collected in the 575-640 nm range. Fluorescent
resonance energy transfer (FRET) was stimulated at 488 nm and collected at 670-810 nm
to avoid any possible overlap with FITC emission wavelengths (see figure 11). All
background staining was adjusted for and standardized when viewing experimental
sections at the same time on the same day.

Figure 11: Fluorescence Resonance Energy Transfer (FRET)
FRET is a distance-dependent interaction between the excited states of two dye molecules. Excitation of a
donor molecule is transferred to an acceptor molecule without photon emission, making it an important
technique for analyzing molecular proximity. J(k) is the spectral overlap integral (90).

Hepatocyte Tissue Culture
(at the Yale Tissue Culture Facility)
150-200g Sprague-Dawley rats were anesthetized with phenobarbital. At
laparotomy, the portal vein was then identified and ligated. Heparin (500units/100g

«
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body weight) was injected into inferior vena cava and allowed to circulate for 1 minute.
The portal vein was cannulated and the IVC was incised to permit a free flow of
perfusate. The liver was then perfused with Hanks A (120 mM NaCl, 5mM KC1, 0.4
mM KH2P04, 0.2 mM Na2P04, 25 mM NaHC03, 0.5 mM EGTA, 0.1% D-Glucose) for
3-4 minutes. Next, the liver was perfused with Hanks B (120 mM NaCl, 5mM KC1, 0.4
mM KH2P04, 0.2 mM Na2P04, 25 mM NaHC03, 0.4 mM MgS04, 0.5 mM MgCl2, 3
mM CaCl2, 0.1% D-Glucose) with collagenase (0.05%/400ml Hanks B) until liver
digestion became visible. The liver was then excised and rinsed in Leibovitz L-15 media
(Life Technologies, Rockville, MD). Glisson's capsule was removed and the digested
parenchyma was manually harvested. The tissue suspension was filtered sequentially
through an 80 pm mesh followed by a 45 pm mesh. The suspension was then
centrifuged at 4°C for 2 minutes at 400 rpm and the pellet was resuspended in 14 mL of
saline buffer. This step was repeated, resuspending the final pellet in 7mL.

Co-Immunoprecipitation
(performed with Michael Eisenberg)
4.5x10s adult male rat hepatic cells from culture were vortexed in 1150 pL of
lysis buffer (140 mM NaCl, 10 mM KC1, 8.2 mM Na2HP04, 1.5 mM KH2P04, 1 mM
DTT, 1 mM PMSL, 1 mM Benzamadine, 1% Triton, pH=7.5). Lysates were cleared of
insoluble material by centrifugation at 14,000 rpm for 10 minutes at 4 °C. The
supernatant was precleared with 20 pL of a 1:1 slurry of Protein G-Agarose (Sigma
Chemical Company, St. Louis, MO) and PBS for 1 hour at 4 °C. The supernatant was
separated by centrifugation at 1,500 rpm for 1 minute and precipitated with 20 pL of
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Protein G beads (incubated overnight at 4 °C with 1 |ig of either anti-[R or anti-GLUT2
antibody). The beads were collected by centrifugation for 6 minutes at 4 °C and washed
twice with Solution I (400mM NaCl, 50mM Tris/HCl, 0.02% sodium azide) and with
Solution II (500mM NaCl, 10mM Tris/HCl, 0.02% sodium azide). The beads were then
isolated by centrifugation at 6,000 rpm for 4 minutes at 4 °C. GLUT2 and IR were
eluted with 60 pL of reducing buffer at 100 °C for 3 minutes. The same protocol was
used to immunoprecipitate GLUT2 and IR with antibodies to the hepatocyte membrane
sodium potassium ATPase (donated by Dr. Michael Kashgarian, Yale University), to be
used as a control protein for comparison.

Electrophoresis and Immunoblotting
Samples were separated by SDS-PAGE on a 7.5% acrylamide gel (Bio-Rad,
Hercules, CA) and electrotransferred to a nitrocellulose membrane (Bio-Rad).
Membranes were blocked with 3% skim milk for 1 hour, washed with PBS-1% Tween
20, and probed with rabbit anti-IR antibody (1:250, Santa Cruz), or blocked with 5%
BSA for 1 hour, washed, and probed with donkey anti-GLUT2 antibody (1:500, Santa
Cruz) for 1 hour. Membranes were then washed, incubated in anti-rabbit IgG (1:1000,
Amersham Life Science Ltd, Buckinghamshires, England) or anti-donkey IgG (1:10000,
Pierce Chemical Co.) for 1 hour. The HRP linked secondary antibody was analyzed with
the ECL immunodetection system (Amersham Life Science Ltd.). Protein bands were
analyzed with scanning densitometry (Personal Densitometer, Molecular Dynamics,
Sunnyvale, CA) and ImageQuaNT™ software (Molecular Dynamics). The expected
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molecular weights for IR were taken at 95kDa and for GLUT2 at 59 kDa. The data was
normalized to an internal control of total cell lysate run on each gel.
All data are represented as a mean ± the standard error of the mean, unless
otherwise stated. Statistical analysis were performed by the student's t-test. Values of p
less than 0.05 were regarded as significant.
All experiments heretofore were conducted by Ajay V. Maker unless otherwise
stated. The induction of chronic pancreatitis and liver harvests were performed with the
assistance of Jinping Wang, M.D., and Lori Slezak, M.D.
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Results

Phosphorylation studies

Duodenal feeding resulted in an increase in phosphorylation of tyrosine residues
on IR (IR-P-Tyr) in sham animals. IR protein recovery revealed no significant change
between sham and CP samples, nor between fasted and fed animals. All comparisons
were made on samples run on the same gel and analyzed concurrently. Corrected for IR
quantity, ER-P-Tyr increased 395 ±112 optical density units (ODU) (p<0.005) over the
fasted state in sham rats. This corresponded to over a 20-fold increase (p<0.05) in P-Tyr
in the sham fed state over the fasted state. IR-P-Tyr also increased in CP animals by 326
± 87.7 ODU (p<0.005) in the fed state, however, this corresponded to only a 9-fold
increase in tyrosine phosphorylation over the fasted state (p<0.005). Thus, CP animals
demonstrate about 12-fold (p<0.05) less Tyr phosphorylation compared to sham animals
upon feeding.
In a similar manner, phosphorylation of serine residues on GLUT2 (GLUT2-PSer) increased in 5/5 sham fed animals, while decreasing in CP fed animals.
Densitometric quantification of phosphorylation was corrected for GLUT2 protein
volume for each sample. Sham animals increased 4.83 (fold) ± 1.2 upon feeding while
CP animals increased only 0.13 (fold) ± .77. This corresponded to almost 5-fold ± 1.19
(p<0.05) less Ser phosphorylation in CP vs. sham animals (see figures 12-14).

»
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IR Tyrosine Phosphorylation

IR protein

Figure 12: IR tyrosine phosphorylation
In this representative Western blot, IR probed with an anti-phosphotyrosine antibody
demonstrates significant increases in total tyrosine phosphorylation in the fed state over the fasted state.
Note the gross increase in phosphorylation in the sham animals in response to feeding and the relatively
diminished increase in phosphorylation in animals with CP. There is no significant difference in the total
amount of IR protein in the different experimental groups, either sham or CP, fasted (fs) or fed (fd).
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GLUT2 Serine Phosphorylation
Figure 13: GLUT2 Serine Phosphorylation
In this representative Western blot, there are significant increases in total GLUT2 serine
phosphorylation in the sham fed (Shfd) state over the sham fasted (Shfs) state versus a relatively
diminished change in phosphorylation in response to feeding in animals with CP.

Figure 14: Feeding induced phosphorylation
Sham animals demonstrate ~20-fold increase in insulin receptor tyrosine phosphorylation (IR-PTyr) and ~5-fold increase in GLUT2 serine phosphorylation (GLUT2-P-Ser) in response to feeding. CP
animals reveal ~ 12-fold less increase in IR-P-Tyr and ~5-fold less GLUT2-P-Ser in response to feeding.

Total PTPase relative activity of sham fed animals was 1.10 ± .14 vs. .913 ± .13
in CP fed animals (n=3,3), revealing no significant relative differences in sham vs. CP
fed livers (see figure 15).

Colocalization Studies

Hepatic Histology
Snap frozen sections of rat hepatic tissue stained by H and E were reviewed after
rehydration. The tissue appeared healthy and displayed normal sinusoidal architecture
(data not shown).
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Protein Amt. (jug)
Figure 15: Phosphotyrosine Phosphatase (PTPase) Assay
One possible reason for decreased phosphorylation could be an increase in tyrosine phosphatase activity.
No significant changes in total non-IR specific PTPase activity were noted between the sham and CP
groups.

Immunolocalization of GLUT2 with goat anti-GLUT2 and anti-goat FITC
The cellular localization of GLUT2 in the adult rat liver is shown in figure 16.
Numerous hepatocytes show positive cell membrane staining with punctate low signal
cytoplasmic staining. The nucleus is clearly visualized.

Immunolocalization of IR with rabbit anti-IR and anti-rabbit Texas Red
The cellular localization of IR in the adult rat liver is shown in figure 16.
Numerous hepatocytes show positive cell membrane staining with punctate low signal
cytoplasmic staining. The nucleus is clearly visualized.
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Colocalization of GLUT! and IR and Fluorescent Resonance Energy Transfer (FRET)
in the hepatocyte
The same sections of hepatic tissue used to localize GLUT2 and IR independently
are superimposed upon each other and viewed in RGB mode. The strongest signals
present are on the hepatocyte cell membrane. The majority of cells are seen to display a
yellow halo effect in areas where pixels of FITC labeled GLUT2 and Texas Red labeled
IR colocalize on the periphery of the cells.
Assuming the absorption spectrum of the acceptor (525-610 nm for Texas Red)
overlaps with the fluorescence emission spectrum of the donor (520-600 nm) for FITC,
FRET depends on the inverse of the sixth power of intermolecular separation. That
distance at which energy transfer occurs is between 10-100 Angstroms. To be more
exact in the case of GLUT2 and IR, we approximated the Forster radius (R0) based on the
spectral properties of the donor and acceptor dyes, that is, the distance at which energy
transfer is 50% efficient and 50% of excited donors are deactivated. R0= (8.8 x 1024 x
K2 x n"4 x QYd x J(A.)) 1/6 Angstroms, where K2 = the dipole orientation factor, QYD the fluorescence quantum yield of the donor in the absence of the receptor, n = the
refractive index, and J(X) = the spectral overlap integral. Using the donor/acceptor pair
of FITC and tetramethylrhodamine (a dye with similar spectral properties to Texas Red),
the Forster radius is approximated to ~55 Angstroms (90).
Samples stimulated in the FITC frequency and collected in the Texas Red
emission spectra reveal immunofluorescence on the hepatocyte membrane and diffusely
throughout the cytoplasm.

'
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Figure 16: Double-labeled immunofluorescence colocalization of GLUT2 and IR
In these representative images, IR is localized to the cell membrane with FITC (green) conjugated
secondary antibody (upper left panel). GLUT2 is localized to the cell membrane with Texas Red (red)
conjugated secondary antibody (upper right panel). When both images are viewed together (lower left),
colocalization is evident by yellow pixels in areas where GLUT2 and IR are in close proximity.
Fluorescent resonance energy transfer (lower right) demonstrates immunofluorescence in the Texas Red
emission spectrum after excitation in the FITC spectrum, implying colocalization within 100 Angstroms.
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Confocal Microscopy Controls
There is an absence of signal when samples were stimulated for either FITC or
Texas Red and emission is collected in both spectra for: blocking solution only, blocking
solution only and both secondary antibodies independently and together, only primary
antibodies independently and together, rabbit anti-IR primary and anti-goat FITC, and
goat and-GLUT2 primary and anti-rabbit Texas Red.

Co-i mmun op recip i ta tion
IR and GLUT2 amounts are expressed as a ratio of total cell lysate signal. When
probed for the presence of IR, lysates precipitated with anti-GLUT2 recovered 40.2% of
the IR compared to precipitations done with anti-IR antibody (0.43 +/- 0.06 au vs. 1.07
+/- 0.11 au). When probed for the presence of GLUT2, lysates precipitated with anti-IR
recovered 25.6% of the GLUT2 compared to precipitations done with anti-GLUT2
antibody (0.31 +/- 0.03 au vs. 1.21 +/- 0.31 au). These results were a significant
deviation (p<0.05) from an irrelevant control antibody to the hepatocyte membrane
sodium potassium ATPase, which recovered 1.2% of IR and 1.8% of GLUT2 (see figure
17).

Absorbance ratio (immunoprecipitate:total cell lysate)

39

Figure 17: Co-immunoprecipitation of insulin receptor and glucose transporter 2
When probed for the presence of IR, lysates precipitated with antibodies against GLUT2 recovered 40.2%
of the IR compared to precipitations done with anti-IR antibody. When probed for the presence of
GLUT2, lysates precipitated with antibodies against IR recovered 24.2% of the GLUT2 compared to
precipitations done with anti-GLUT2 antibody. Hepatocyte transmembrane antibody against Na, K
ATPase recovered only 1.2% of IR and 1.8% of GLUT2.
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Discussion

Autophosphorylation of tyrosine residues on IR upon insulin binding may be the
first response to the hormone and mediates intracellular protein kinase activities,
including glucose regulation (91). Our data demonstrate a 20-fold increase in IR-Tyr
phosphorylation and ~5-fold increase in GLUT2-Ser phosphorylation after feeding in
sham animals. Although previous studies have shown similar trends in IR-kinase
autophosphorylation, these effects have been induced by exogenous or in vitro
administration of insulin (92). The response seen in sham rats after feeding, therefore,
confirms an in vivo physiologic model of insulin action that is clinically applicable. In
the present study, we have also examined IR and GLUT2 phosphorylation in hepatic
cells of both normal and CP rats, and have shown that feeding-stimulated
autophosphorylation of IR-Tyr is inhibited ~ 12 fold and that GLUT2-Ser
phosphorylation is decreased ~5 fold in animals with pancreatogenic diabetes.
Activation of a receptor-kinase by IR-Tyr autophosphorylation could be a key
mechanism in activating intracellular phosphorylation-dephosphorylation cascades.
Furthermore, autophosphorylation of IR alone may be a sufficient catalyst, independent
of protein kinase and phosphatase activity, in stimulating the physiologic response of
insulin. Therefore, the diminished IR-Tyr phosphorylation can account, at least in part,
for the insulin resistance exhibited by rats with pancreatogenic diabetes (93, 94).
Additional studies to address the possibility of receptor downregulation, IR trafficking,
and ligand binding affinity may further elucidate the molecular mechanisms involved.
Alternatively, decreased IR-Tyr phosphorylation may be the first step, with or without
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decreased activation of a second messenger, ultimately affecting GLUT2
phosphorylation and glucose transport out of the hepatocyte. That this mechanism is
dysfunctional in CP may account for uninhibited hepatic glucose production and
subsequent hyperglycemia.
Previous studies in vitro have demonstrated changes in glucose transport rates in
beta-cells directly accountable to changes in serine phosphorylation, and our results
imply a similar in vivo mechanism with liver GLUT2 (83). The hepatocyte, however, is
unique in that glucose efflux is associated with the fasted state, while the fed state is
associated with a decreased rate of transport, or inhibited glucose efflux, i.e. in response
to an insulin surge. Thus, our data support that the translocation of GLUT2 on and off
the hepatocyte cell membrane may be directly linked to the phosphorylation state of the
protein, accounting for the dysfunction of hepatic GLUT2 translocation in response to
feeding seen in CP (32). Dominant negative or kinase dead insulin receptor studies that
compare IR and GLUT2 phosphorylation states may address this mechanism.
Accordingly, this characteristic of the hepatocyte implies the opposite direction of net
glucose transport, and GLUT translocation, compared to every other cell in the body
under the same conditions. It also appears that hepatic GLUT2 functions inversely to
GLUT4, with phosphorylation of the transport protein causing a decrease in GLUT2
mediated glucose transport simultaneously with an increase in GLUT4 mediated glucose
transport.
The cascade initiated by ligand-receptor binding is regulated by a reciprocal
quenching of transduction by the receptor. The mechanisms of quenching are involved
in inhibiting the IR response, and include receptor internalization via endocytosis,
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receptor desensitization by feedback phosphorylation, receptor ubiquitination and
degradation or decreased expression, and dephosphorylation via PTPases. In the CP
model studied in our laboratory, IR internalization is inhibited, as measured by an
endosome to plasma membrane ratio (84), IR expression has been shown to be reduced
(67), and membrane bound IR is diminished (93), though we did not see a significant
difference in the total hepatocyte IR purified between sham and CP animals. We have
controlled for this possible decrease in plasma membrane IR by expressing and
comparing changes in IR-P per amount of IR purified from the cell. It is possible,
however, that receptor desensitization by feedback phosphorylation of serine and
threonine residues on the IR modulates the insulin response, and this needs to be
investigated further in the CP model (33). Previous studies on aged rats have
demonstrated insulin resistance to be associated with decreased hepatic IR
autophosphorylation, due to elevated IR PTPase activity (95). In addition, studies have
shown that the impaired translocation of GLUT4 resulting from overexpression of PTP
IB can be reversed when cells are treated with a PTPase inhibitor (96). Therefore, we
chose to investigate if the decrease in IR phosphorylation in pancreatogenic diabetes was
secondary to increased tyrosine PTPase activity. Our total PTPase assay revealed that
total tissue PTPase activity is not significantly altered in CP. However, it is possible that
IR tyrosine-specific PTPase activity may account for the results observed (73). Further
studies to assess this possibility are currently in progress.

Insulin binding to the insulin receptor induces a conformational change and
autophosphorylation of the intracellular beta subunit, propagating activation of multiple
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downstream targets, including PI3-kinase. Recently, multiple new components of the
insulin receptor signaling cascade have been discovered and their cDNA clones isolated.
Particularly exciting has been the current implications of PI3 kinase and Akt/PKB
activation as a required component in glucose transport regulation by insulin in skeletal
muscle cells, adipocytes, and in the liver (51, 71, 72). To date, however, there has been
no study to imply a direct connection between the IR and a glucose transport protein,
either spatially or chemically.
The importance of hepatic glucose production and regulation, however, cannot be
over emphasized, and the role of the low affinity, high Km hepatic glucose transport
protein GLUT2 in response to insulin is as yet unclear. Previous experiments in our
laboratory have confirmed a parallel increase in endosome to plasma membrane ratios
upon feeding in both IR and GLUT2, suggesting physical or signal coupling between the
proteins (84). Moreover, studies have correlated glucose transport with the in vitro
phosphorylation state of GLUT2 (83), and our current study shows decreased
phosphorylation of both GLUT2 and IR in CP, implying an intimate connection between
GLUT2 and a kinase, or a series of kinase proteins in the hepatocyte. These data, in
conjunction with insulin resistant and frankly diabetic syndromes with genetic defects in
GLUT2, i.e., Fanconi-Bickel syndrome and homozygous GLUT2 knockout mice, support
a cell-signaling relationship between insulin, via the hepatic IR, and GLUT2.
We show, for the first time, that GLUT2 is colocalized spatially and chemically to
the hepatic IR, supporting their function as a receptor/transporter complex. GLUT2 and
IR can be co-immunoprecipitated significantly relative to a ubiquitous non-tyrosine
kinase hepatocyte protein, displaying ~33-fold recovery of IR by an anti-GLUT2
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antibody over the control, and -14 fold recovery of GLUT2 by an anti-IR antibody over
the control. Further experiments to specifically address differences in phosphorylated
amino acid residues between co-immunoprecipitated and non-co-immunoprecipitated
proteins may strengthen the argument for a receptor-transporter communication complex.
That each protein co-precipitates a fraction of the other implies that they are not
complexed together in all parts of the cell. A significant portion of each must exist
independent of the other, though some of these pools may be subunits of whole protein,
inactive molecules, or compartamentalized intracellularly. That -25% of GLUT2 is
bound to all of the hepatocyte IR suggests alternate regulation of the protein 3/4 of the
time. Flowever, it is important to note that significantly more (40%) IR co-precipitates
when immunoprecipitated with all of the hepatocyte GLUT2, demonstrating that GLUT2
more often colocalizes with IR than vice-versa. It is known that the majority of GLUT2,
over 90%, sits on the hepatocyte membrane (97), therefore, it is feasible to conclude
from the data that colocalization is more quantifiable on the cell membrane than
intracellularly, and this is supported by confocal microscopy imaging.
Double label immunofluorescence has been established as a method of
colocalization in a number of studies (98-101). Although IR has been colocalized with
IGF/IR hybrid receptors, GLUT4 has been localized to the cell surface, and GLUT2 has
been localized to the beta cell membrane, IR has not been studied in relation to GLUT2
or 4 (82, 102-104).

When viewed with confocal microscopy in our experiments, both

GLUT2 and IR clearly colocalize on the hepatocyte membrane. FRET analysis of the
liver tissue confirms energy transfer between the proteins of interest. That distance at
which energy transfer occurs is calculated to be between 10-100 Angstroms. To be more
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exact in the case of GLUT2 and IR, we calculated the Forster radius (R0) based on the
spectral properties of similar donor and acceptor dyes, at approximately 55 Angstroms.
Combined, these data support a unique and specific physical interaction between the
proteins. It is implied from these results that GLUT2 and IR maintain a fixed spatial
relationship as a complex on the cell membrane and through endocytosis.
In conclusion, it has been shown that phosphorylation defects in the hepatic IR
are concomitant with decreased phosphorylation in GLUT2 in pancreatogenic diabetes.
Our data imply that this parallel deficiency may not be coincidental, but secondary to a
direct cellular signaling cascade from the IR to GLUT2. It is possible that defects in this
cross-talk between hepatic GLUT2 and IR are responsible for insulin resistance and
unimpaired hepatic glucose production seen in pancreatogenic diabetes. The
dysfunction may be at the level of the IR, in intermediate signaling proteins, in docking
and fusion proteins, or in spatial relationships between GLUT2 and IR, opening further
directions for study into the phosphorylation states of PI3 kinase, Akt/PKB, and IRS
proteins; the functional roles of vesicle associated membrane proteins (VAMPs), soluble
N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), and other
vesicle proteins; and real time atomic force microscopy of IR-GLUT2 interactions.
Furthermore, it appears that hepatic GLUT2 and IR are arranged on the
hepatocyte membrane in a specific spatial relationship. That they co-immunoprecipitate
significantly relative to a ubiquitous control protein implies an alternate, functional
cytoarchitectural arrangement. We therefore propose that an IR-GLUT2 complex exists
in hepatocytes, and that this receptor-transporter unit serves as the principal regulatory
mechanism of hepatic glucose production. Together, these novel experiments introduce
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an elegant intracellular relationship between a receptor and a transporter, explaining how
the insulin response is propagated, how involved proteins are signaled and translocate,
and how dysfunction causes insulin resistance; stimulating exciting directions for further
research in cell signaling of the IR and the molecular mechanisms of insulin resistance.
Pharmacologic and gene targeting of these defects holds promise for the future of
patients with pancreatogenic diabetes and diabetes mellitus.
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